Published in Medical Letter on the CDC and FDA, October 24th, 2004
"Sarpogrelate is a selective 5-hydroxytryptamine receptor subtype 2A (5-HT2A ) antagonist. It is metabolized to racemic M-1 and both enantiomers of M-1 are also antagonists of 5-HT2A receptors. Sarpogrelate inhibits responses to 5-HT mediated by 5-HT2A receptors such as platelet aggregation, vasoconstriction, and vascular smooth muscle proliferation. There is no information available on the pharmacokinetics of sarpogrelate," a scientist in New Zealand reports.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA